Table 1.
Demographic, immunological and clinical characteristics of Study populations 1 and 2.
| Study population-1 | Study population-2 | |||||
|---|---|---|---|---|---|---|
| All | BMI ≥ 25 Kg/m2 | BMI < 25 Kg/m2 | p-value | p-value* | ||
| N | 176 | 89 | 87 | 54 | ||
| Age, years | 56 ± 15 | 58 ± 13 | 53 ± 16 | 0.02 | 57 ± 12 | |
| Symptom#/Disease##'s duration, months#/years## | 5.6 ± 3.5 | 5.2 ± 3.2 | 6.1 ± 3.6 | 0.09 | 5.9 ± 3.6 | |
| Sex, n. female (%) | 135 (76.7) | 63 (70.8) | 72 (82.8) | 0.06 | 46 (85.2) | |
| BMI, Kg/m2 | 25.3 ± 4.8 | – | – | – | 35.2 ± 4.1 | |
| Overweight, n(%) | 63 (35.8) | – | – | – | 4 (7.4) | |
| Obesity, n(%) | 26 (14.8) | – | – | – | 50 (92.6) | |
| ACPA positivity, n(%) | 104 (59.1) | 54 (60.7) | 50 (57.5) | 0.67 | 46 (48.1) | |
| RF-IgM positivity, n(%) | 84 (47.7) | 46 (51.7) | 39 (44.8) | 0.36 | 22 (40.7) | |
| RF-IgA positivity, n(%) | 51 (29.0) | 30 (33.7) | 21 (24.1) | 0.16 | 14 (25.9) | |
| ESR, mm/1∧hour | 41.4 ± 28.7 | 44.3 ± 27.7 | 38.5 ± 29.5 | 0.07 | 0.49 | 35.3 ± 22.9 |
| CRP, mg/l | 21.3 ± 31.5 | 25.7 ± 36.4 | 16.8 ± 25.0 | 0.02 | 0.24 | 9.5 ± 10.8 |
| IL6, pg/ml | 21.7 ± 42.6 | 26.7 ± 43.1 | 13.8 ± 21.3 | 0.01 | 0.09 | 10.7 ± 20.2 |
| sIL6-R, ng/ml | 56.2 ± 19.3 | 57.8 ± 22.1 | 54.8 ± 16.8 | 0.85 | 0.83 | 47.3 ± 23.9 |
| TJC | 11.3 ± 6.9 | 12.28 ± 7.29 | 10.32 ± 6.41 | 0.06 | 0.04 | 5.6 ± 4.2 |
| SJC | 8.4 ± 5.8 | 8.80 ± 5.51 | 7.91 ± 6.04 | 0.13 | 0.37 | 3.7 ± 3.2 |
| HAQ | 1.1 ± 0.8 | 1.25 ± 0.75 | 1.01 ± 0.76 | 0.02 | 0.08 | 1.1 ± 0.6 |
| DAS | 3.4 ± 0.9 | 3.5 ± 1.0 | 3.3 ± 0.9 | 0.02 | 0.09 | 2.8 ± 0.8 |
| SDAI | 29.3 ± 14.3 | 30.8 ± 14.3 | 27.8 ± 14.3 | 0.09 | 0.36 | 15.8 ± 9.3 |
| bDMARDs, n(%) | – | – | – | – | – | 25 (46.3) |
| Chemerin, ng/ml | 108.6 ± 52.2 | 120.7 ± 57.1 | 96.2 ± 43.6 | 0.002 | 0.01 | 53.7 ± 19.0 |
| PEDF, μg/ml | 13.1 ± 3.9 | 13.7 ± 3.9 | 12.5 ± 3.8 | 0.02 | 0.18 | 16.5 ± 3.2 |
Values are mean ± standard deviation unless otherwise indicated. ERA, early rheumatoid arthritis; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS, disease activity score; ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; TJC, tender joint count; SJC, swollen joint count; HAQ, Health Assessment Questionnaire; SDAI, simplified disease activity index; bDMARDs, biological Disease Modifying Anti-Reumatic Drugs; PEDF, pigment epithelium-derived factor.
for Study population-1 and
for Study population-2.
P-value: Mann-Withney test overweight/obese patients vs. normal weight patients.
P-value*: Mann-Withney test overweight/obese patients vs. normal weight patients corrected for age and sex.
P-value < 0.05 were considered statistically significant.